Positive Phase II For Sanofi-Chasing Valneva/GSK C.Diff Vaccine
This article was originally published in Scrip
Valneva has reported positive topline Phase II data for its prophylactic vaccine candidate against Clostridium difficile infection. The product – which is partnered with GlaxoSmithKline – is the second in development behind Sanofi's prophylactic vaccine candidate, claims Valneva CEO Thomas Lingelbach. He also believes Valneva's product could offer advantages over Sanofi's product. Pfizer also has a prophylactic C. difficile vaccine candidate in Phase II development.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.